Limitar la búsqueda a ejemplares disponibles

Cubierta del libro

Título Specific immunotherapy of cancer with vaccines / edited by Jean-Claude Bystryn, Soldano Ferrone, and Philip Livingston

Publicación New York : New York Academy of Sciences, 1993
Ubicación Signatura Tipo de préstamo Estado Notas
 Ciencias.Física/Química-Bioquímica y Biología Molecular y Celular  BQ Anel-33    CONSULTAR DEPT  DISPONIBLE
Descripción física XII, 411 p. : il. ; 24 cm
Colección Annals of the New York Academy of Sciences, ISSN 0077-8923 ; 690
Annals of the New York Academy of Sciences ; 690
Nota Proceedings of a conference held by the New York Academy of Sciences, Jan. 21-24, 1993, in Washington, D.C
Bibliografía Bibliografía por capítulos. -- Índices p. 403-411
Contiene: ━ Part I. Foundations for Therapy of Cancer with Vaccines: Conference Overview -- The Promise and the Reality of Viral Vaccines against Cancer -- Lessons from Autoimmunitya -- Tumor Immunology: An Overview ━ Part II. Immune Mechanisms Relevant to Vaccine Effectiveness: Tolerance and Ways to Break Ita -- Tumor Escape from Immune Response by Variation in HLA Expression and Other Mechanisms ━ Part III. Human Tumor Antigens Relevant for Vaccine Construction: Tumor Antigens Known to be Immunogenic in Man -- Recognition of Autoantigens by Patients with Melanoma -- The Polymorphic Epithelial Mucin as a Target for Immunotherapy -- Immune Response to Genital Papillomavirus Infections in Women Prospects for the Development of a Vaccine against Cervical Cancer -- Transformation‐Associated Epstein‐Barr Virus Antigens as Targets for Immune Attack -- T‐Cell Immunity to Oncogenic Proteins Including Mutated RAS and Chimeric BCR‐ABL -- Genes Coding for Antigens Recognized on Human Tumors by Autologous Cytolytic T Lymphocytes
━ Part IV. Rationale for Vaccine Construction and Results of Clinical Trials: ━ Whole Cell Vaccines: Polyvalent Melanoma Vaccine Improves Survival of Patients with Metastatic Melanoma -- Active Specific Immunotherapy of Human Colorectal Carcinoma with an Autologous Tumor Cell/Bacillus Calmette‐Guérin Vaccine -- Treatment of Human Melanoma with a Hapten‐Modified Autologous Vaccine ━ Cell Lysate Vaccines: Active Specific Immunotherapy of Melanoma with Allogeneic Cell Lysates Rationale, Results, and Possible Mechanisms of Action ━ Viral Oncolysate Vaccines: Evaluation of Vaccinia Viral Lysates as Therapeutic Vaccines in the Treatment of Melanoma -- Clinical Trials with VMO for Melanoma ━ Shed Antigen Vaccines: Immunogenicity and Clinical Activity of a Polyvalent Melanoma Antigen Vaccine Prepared from Shed Antigens ━ Ganglioside Vaccines: Approaches to Augmenting the IgG Antibody Response to Melanoma Ganglioside Vaccines -━ Anti‐ID Vaccines: Human Tumor‐Associated Antigen Mimicry by Anti‐idiotypic Antibodies Immunogenicity and Clinical Trials in Patients with Solid Tumors ━ Genetically Engineered Vaccines: On the Role of Costimulation in Tumor Immunity -- Specific and Effective T‐Cell Recognition of Cells Transfected with a Truncated Human Mucin cDNA -- Genetically Engineered Vaccines Comparison of Active versus Passive Immunotherapy against Solid Tumors
━ Part V. Approaches for Potentiating Vaccine Immunogenicity: Epitope Selection and Design of Synthetic Vaccines Molecular Approaches to Enhancing Immunogenicity and Cross‐Reactivity of Engineered Vaccines -- Novel Adjuvant Strategies for Experimental Malaria and AIDS Vaccines -- Immune Responses of Mice and Human Breast Cancer Patients following Immunization with Synthetic Sialyl‐Tn Conjugated to KLH Plus Detox Adjuvant -- Immunotherapeutic Strategies for Cancer Using Poxvirus Vectors -- Genetically Engineered Tumor Vaccines ━ Part VI. NCI and FDA Perspective on Cancer Vaccines: Vaccines for Human Cancers of Viral Etiology -- Cancer Vaccines: The Perspective of the Cancer Immunology Branch, NCI
━ Poster Papers: Active Specific Immunotherapy of Murine Colon Adenocarcinoma with Recombinant Vaccinia/Interleukin‐2‐Infected Tumor Cell Vaccines -- Immunization with Human Monoclonal Antiidiotypic Antibody in Colorectal Cancer -- Immunization Effect of Monoclonal Antibodies against Tumor‐Associated Antigens during Cancer Treatment -- Assessment of Immunologic Competence and Host Reactivity against Tumor Antigens in Breast Cancer Patients: Prognostic Value and Rationale of Immunotherapy Development -- Augmentation of T‐Cell Response with a Melanoma Cell Vaccine Expressing Specific HLA‐A Antigens -- Transfection of TGF‐β Producing Tumors with IL‐2 Elicits Tumor Rejection -- Coexpression of IL‐2 and γ‐IFN Enhances Tumor Immunity -- Active Specific Immunotherapy of Hodgkin's Lymphoma by an Anti‐idiotype Vaccine against the Hodgkin‐Associated CD30 Antigen -- Pancarcinoma T/Tn Antigen Detects Human Carcinoma Long before Biopsy Does and Its Vaccine Prevents Breast Carcinoma Recurrence -- Phase Ib Trial of a Synthetic β Human Chorionic Gonadotropin Vaccine in Patients with Metastatic Cancer -- Adjuvant Vaccination in Colorectal Carcinoma -- Specific Immunotherapy of Colorectal Carcinoma with Newcastle‐Disease Virus‐Modified Autologous Tumor Cells Prepared from Resected Liver Metastasis -- Randomized Study of Adjuvant Immunotherapy with Autologous Tumor Cells and BCG in Renal Cancer -- Specific Immunotherapy Using a Recombinant Vaccinia Virus Expressing Human Carcinoembryonic Antigen -- Identification and Characterization of a Colon Tumor‐Associated Antigen -- Antiidiotype (Ab2) Vaccine Therapy for Cutaneous T‐Cell Lymphoma -- A Potential Surrogate Marker of Efficacy for a Therapeutic Melanoma Vaccine -- Enhancement of a Spontaneous Immune Response against a B‐Cell Lymphoma by Dendritic Cells Leads to Protection against the Tumor -- Clinical Trials of Idiotype‐Specific Vaccine in B‐Cell Lymphomas -- Clinical Responses to Intralymphatic Whole‐Cell Melanoma Vaccine Augmented by in Vitro Incubation with Alpha‐Interferona -- Adjuvant Activity of QS‐21 Isomers -- Construction of Immunogenic GD3‐Conjugate Vaccines -- Comparison of the Binding Parameters to Melanoma Cells of Antihuman High Molecular Weight‐Melanoma Associated Antigen (HMW‐MAA) Monoclonal Antibodies (mAb) and Syngeneic Anti‐Anti‐idiotypic (Anti‐Anti‐id) mAb
Materia Cáncer -- Inmunoterapia -- Congresos
       Mostrar referencias similares
Vacunas -- Congresos
       Mostrar referencias similares
Inmunoterapia -- Congresos
       Mostrar referencias similares
Tumores -- Tratamiento -- Congresos
       Mostrar referencias similares
Autor secundario Bystryn, Jean-Claude, ed. lit.
Ferrone, Soldano, ed. lit.
Livingston, Philip, ed. lit.
New York Academy of Sciences, ed.
ISBN 0897668251